Cynosure Group LLC Has $1.20 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Cynosure Group LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 26.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,560 shares of the company's stock after selling 562 shares during the quarter. Cynosure Group LLC's holdings in Eli Lilly and Company were worth $1,204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Private Portfolio Partners LLC increased its position in shares of Eli Lilly and Company by 16.8% in the 4th quarter. Private Portfolio Partners LLC now owns 3,189 shares of the company's stock worth $2,462,000 after purchasing an additional 459 shares during the last quarter. Kesler Norman & Wride LLC increased its holdings in Eli Lilly and Company by 18.9% in the fourth quarter. Kesler Norman & Wride LLC now owns 4,774 shares of the company's stock valued at $3,685,000 after buying an additional 760 shares during the last quarter. RFG Bristol Wealth Advisors LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $2,071,000. Meeder Advisory Services Inc. raised its stake in Eli Lilly and Company by 3.4% during the fourth quarter. Meeder Advisory Services Inc. now owns 16,302 shares of the company's stock valued at $12,585,000 after buying an additional 541 shares in the last quarter. Finally, Groupama Asset Managment lifted its holdings in Eli Lilly and Company by 3.8% during the 4th quarter. Groupama Asset Managment now owns 91,838 shares of the company's stock worth $71,068,000 after buying an additional 3,373 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Remove Ads

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $14.34 during trading on Wednesday, reaching $819.57. The company had a trading volume of 2,678,114 shares, compared to its average volume of 3,311,810. The firm's fifty day moving average is $848.85 and its 200 day moving average is $834.05. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market capitalization of $777.09 billion, a PE ratio of 69.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a share buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LLY. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a report on Thursday, March 6th. Bank of America reissued a "buy" rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,009.72.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.